News

Verrica received a Complete Response Letter from the FDA regarding their New Drug Application for the topical molluscum contagiosum treatment, VP-102.

An expert cautions against panic but advises careful study and robust public health response.

RBX2660, an investigational microbiota-based live biotherapeutic for the treatment of C difficile, safely and effectively reduced recurrent C diff for 6 months.

With limitations on fidaxomicin at their facility, a hospital looked at vancomycin usage to determine if they needed to align with the new IDSA/SHEA CDI treatment guideline.

New information suggests a few more cases have surfaced in the United States, pending CDC confirmation.

A team of investigators studied Clostridioides difficile infection (CDI) isolates to gauge resistance in the 2 antibiotics.

Seres Therapeutics shared phase 3 trial results demonstrating their investigational microbiome-based therapeutic, SER-109, prevented recurrent C difficile infection (rCDI) in 88% of recipients.

Companies say the 3 doses of their vaccine meet all immunobridging criteria required for the Emergency Use Authorization (EUA).

A health system piloted a program that explored having an infectious disease pharmacist aid in guiding treatment.

Designing a transitions of care stewardship program and engaging all stakeholders can help cut down on unnecessary antibiotic prescriptions.

Can clinicians rely on dosing strategy to avoid acute kidney injury for patients receiving vancomycin with a β-lactam like piperacillin-tazobactam?

Investigators sought information on how the infection is treated in outpatient clinics

Jason Pogue, PharmD, BCPS, BCIDP, shares key takeaways from his 2 presentations at MAD-ID 2022, including a new alternative to the SPACE acronym, as well as how to navigate any anxieties around oral carbapenems.

A MAD-ID 2022 poster sought to better understand the current antibiotic prescribing patterns at adult primary care clinics affiliated with Maimonides Medical Center in New York.

In a poster presented at MAD-ID 2022, Margaret Pertzborn, PharmD, evaluated the efficacy of a PrEP Provider Toolkit on non-infectious disease provider comfort prescribing PrEP with their patients.

A study looked at the utilization of the technology with this antibiotic class in hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP).

In a poster presented at MAD-ID 2022, Glenn S. Tillotson, PhD, FIDSA, FCCP, shares data from the Premier Healthcare Database on more than 100,000 patients with C diff.

AdventHealth Orlando studied a small number of these fungal isolates to examine treatment resistance patterns.

At MAD-ID 2022, Payal K. Patel, MD, MPH, FIDSA, discussed how COVID-19 misinformation and lags in diagnostics contributed to inappropriate antibiotic use and offers some way to combat this trend.

In hospitalized COVID-19 patients, remdesivir stewardship reduced hospital length of stay and therapy duration.

Colleen R. Kelly, MD, FACG, speaks at MAD-ID 2022 on alternatives to antibiotics for C diff infection, including the use of probiotics and fecal microbiota transplantation.

The CDC’s COVID-19 booster dose recommendation for children 5 and older comes a few days after the FDA’s authorization

“Clearly, stewardship is a team operation. It starts [with] the leadership, the clinical pharmacy, and coordination with infectious disease physicians truly has to be synergistic,” Goetz said in the keynote address at MAD-ID 2022.

Among community-acquired pneumonia (CAP) outpatients, 49% were prescribed unnecessary antibiotics.

Leveraging antimicrobial stewardship programs was crucial to ensure COVID-19 hospital inpatients received monoclonal antibody therapy quickly and safely.

To reduce the risk of antimicrobial resistance, rapid laboratory diagnostics are needed to identify the pathogens in hospital patients with COVID-19 and sepsis.

A review of the neutralizing antibody that was studied in a phase 2/3 trial in outpatients with mild to moderate infections of COVID-19.

The FDA lifted a clinical hold on investigational lenacapavir for HIV treatment and pre-exposure prophylaxis. All clinical studies evaluating injectable lenacapavir can now resume.

Today, the International AIDS Vaccine Initiative (IAVI) and Moderna announced they will soon launch a phase 1 clinical trial for their HIV vaccine candidate, administered with mRNA technology to develop broadly neutralizing antibodies.